Pneumococcal vaccine and patients with pulmonary diseases

American Journal of Medicine

Volumn 127, Issue 9, 2014, Pages 886.e1-886.e8

  Mirsaeidi, Mehdi ^a   Ebrahimi, Golnaz ^a   Allen, Mary Beth ^b   Aliberti, Stefano ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Invasive pneumococcal disease; Pneumococcal; Pneumonia; Pulmonary; Streptococcus pneumoniae; Vaccination

Indexed keywords

METHOTREXATE; PNEUMOCOCCUS VACCINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC LUNG DISEASE; DISEASE PREDISPOSITION; HEMATOLOGIC MALIGNANCY; HEMOGLOBINOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LUNG COMPLICATION; LUNG DISEASE; NEPHROTIC SYNDROME; NONHUMAN; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; SICKLE CELL ANEMIA; STEROID THERAPY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84908178893     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.05.010     Document Type: Review

References (88)

1. Prevention CfDCa. Clinical Features: Pneumococcal Disease. Available at: http://www.cdc.gov/pneumococcal/clinicians/clinical-features.html. Accessed March 6, 2014.
2. CDC. Deaths: Preliminary Data for 2011. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-06.pdf. 2012. Accessed April 3, 2014.
3. D.S. Fedson, and J.A. Scott The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known Vaccine 17 Suppl 1 1999 S11 S18
4. H. Yu, J. Rubin, and S. Dunning Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population J Am Geriatr Soc 60 2012 2137 2143
5. J. Henrichsen Six newly recognized types of Streptococcus pneumoniae J Clin Microbiol 33 1995 2759 2762
6. K. Sleeman, K. Knox, and R. George Invasive pneumococcal disease in England and Wales: vaccination implications J Infect Dis 183 2001 239 246
7. M. Mirsaeidi, and D.E. Schraufnagel Pneumococcal vaccines: understanding centers for disease control and prevention recommendations Ann Am Thorac Soc 11 6 2014 980 985
8. J.B. Le Meur, B. Lefebvre, and J.F. Proulx Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010 Int J Circumpolar Health 73 2014 22691
9. W.P. Hausdorff, J. Bryant, and C. Kloek The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II Clin Infect Dis 30 2000 122 140
10. T.Q. Tan, E.O. Mason Jr., and E.R. Wald Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae Pediatrics 110 1 Pt 1 2002 1 6
11. H.L. Johnson, M. Deloria-Knoll, and O.S. Levine Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project PLoS Med 7 10 2010
12. S. Aliberti, M. Mantero, M. Mirsaeidi, and F. Blasi Role of vaccination in preventing pneumococcal disease in adults Clin Microbiol Infect 20 Suppl 5 2014 52 58
13. J.P. Janssens, and K.H. Krause Pneumonia in the very old Lancet Infect Dis 4 2004 112 124
14. R. Austrian, and J. Gold Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia Ann Intern Med 60 1964 759 776
15. CDC Active Bacterial Core surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010 2011 US Department of Health and Human Services, CDC Atlanta, GA Available at: http://www.cdc.gov/abcs/reports-findings/survreports/spneu10-orig.html Accessed April 3, 2014
16. D.F. Smith, and E.F. Boss Racial/ethnic and socioeconomic disparities in the prevalence and treatment of otitis media in children in the United States Laryngoscope 120 2010 2306 2312
17. S.L. Block Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media Pediatr Infect Dis J 16 1997 449 456
18. M.C. Thigpen, C.G. Whitney, and N.E. Messonnier Bacterial meningitis in the United States, 1998-2007 N Engl J Med 364 2011 2016 2025
19. K.A. Robinson, W. Baughman, and G. Rothrock Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era JAMA 285 2001 1729 1735
20. Centers for Disease Control and Prevention Advisory Committee on Immunization P. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23) MMWR Morb Mortal Wkly Rep 59 2010 1102 1106
21. D.M. Musher, I. Alexandraki, and E.A. Graviss Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study Medicine 79 2000 210 221
22. A. Plevneshi, T. Svoboda, and I. Armstrong Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto PloS One 4 2009 e7255
23. E.N. Janoff, and J.B. Rubins Invasive pneumococcal disease in the immunocompromised host Microb Drug Resist 3 3 1997 215 232
24. A. Di Sabatino, R. Carsetti, and G.R. Corazza Post-splenectomy and hyposplenic states Lancet 378 9785 2011 86 97
25. M. Ramakrishnan, J.C. Moisi, and K.P. Klugman Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis Lancet Infect Dis 10 2010 329 337
26. J. Vestbo, S.S. Hurd, and A.G. Agusti Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
27. A. Mor, R.W. Thomsen, S.P. Ulrichsen, and H.T. Sorensen Chronic heart failure and risk of hospitalization with pneumonia: a population-based study Eur J Intern Med 24 2013 349 353
28. I.K. Wang, C.L. Lin, and P.C. Lin Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study PloS One 8 2013 e58317
29. J.P. Nuorti, J.C. Butler, and M.M. Farley Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team N Engl J Med 342 2000 681 689
30. A. Dominguez, C. Izquierdo, and L. Salleras Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Eur Respir J 36 2010 608 614
31. I. Ridda, C.R. Macintyre, and R. Lindley Immunological responses to pneumococcal vaccine in frail older people Vaccine 27 2009 1628 1636
32. D.M. Musher, D.A. Watson, and E.A. Dominguez Pneumococcal vaccination: work to date and future prospects Am J Med Sci 300 1990 45 52
33. C.G. Whitney, M.M. Farley, and J. Hadler Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746
34. R. Malley, K. Trzcinski, and A. Srivastava CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization Proc Natl Acad Sci U S A 102 2005 4848 4853
35. Administration UFaD. Protection of adults from invasive pneumococcal disease (IPD) by means of active immunization with currently licensed vaccine PNEUMOVAX 23TM (PPV23). Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/5-4188b2-4b.pdf. Accessed April 3, 2014.
36. R.E. Biagini, S.A. Schlottmann, and D.L. Sammons Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides Clin Diagn Lab Immunol 10 2003 744 750
37. J.P. Nuorti, and C.G. Whitney Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 59 RR-11 2010 1 18
38. J.C. Butler, R.F. Breiman, and J.F. Campbell Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations JAMA 270 1993 1826 1831
39. L.A. Jackson, and E.N. Janoff Pneumococcal vaccination of elderly adults: new paradigms for protection Clin Infect Dis 47 2008 1328 1338
40. J. Johnstone, D.T. Eurich, and J.K. Minhas Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia Clin Infect Dis 51 2010 15 22
41. D.M. Musher, A.M. Rueda-Jaimes, E.A. Graviss, and M.C. Rodriguez-Barradas Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia Clin Infect Dis 43 2006 1004 1008
42. S. Moberley, J. Holden, D.P. Tatham, and R.M. Andrews Vaccines for preventing pneumococcal infection in adults Cochrane Database Syst Rev 1 2013 CD000422
43. E.A. Blumberg, S.C. Brozena, and P. Stutman Immunogenicity of pneumococcal vaccine in heart transplant recipients Clin Infect Dis 32 2001 307 310
44. S. Tobudic, V. Plunger, and G. Sunder-Plassmann Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients PloS One 7 2012 e46133
45. D. Kumar, M.H. Chen, and B. Welsh A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients Clin Infect Dis 45 2007 1576 1582
46. M.C. Rodriguez-Barradas, D.M. Musher, and C. Lahart Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine J Infect Dis 165 1992 553 556
47. C.C. Hung, S.Y. Chang, and C.T. Su A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy HIV Med 11 2010 54 63
48. Prevention CfDCa. Recommended immunization schedule for persons aged 0 through 18 years - United States. Available at: http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf. 2014. Accessed April 3, 2014.
49. S.S. Richter, K.P. Heilmann, and C.L. Dohrn Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.) Emerg Infect Dis 19 2013 1074 1083
50. C.G. Grijalva, and S.I. Pelton A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children Curr Opin Pediatr 23 2011 98 104
51. Food and Drug Administration (FDA) web site. Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Prevnar®. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm137038.pdf. Accessed April 3, 2014.
52. T. Pilishvili, C. Lexau, and M.M. Farley Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine J Infect Dis 201 2010 32 41
53. R.D. Mistry, T. Wedin, and F. Balamuth Emergency department epidemiology of pneumococcal bacteremia in children since the institution of widespread PCV7 vaccination J Emerg Med 45 2013 813 820
54. Centers for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 62 2013 521 524
55. Centers for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 61 2012 816 819
56. T.F. Schwarz, J. Flamaing, and H.C. Rumke A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years Vaccine 29 2011 5195 5202
57. Centers for Disease Control and Prevention Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010 MMWR Morb Mortal Wkly Rep 59 2010 258 261
58. D.M. Musher How effective is vaccination in preventing pneumococcal disease? Infect Dis Clin North Am 27 2013 229 241
59. Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm?source=govdelivery. Accessed March 28, 2014.
60. L.A. Jackson, A. Gurtman, and M. van Cleeff Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults Vaccine 31 2013 3577 3584
61. K.J. Smith, M.P. Nowalk, M. Raymund, and R.K. Zimmerman Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults Vaccine 31 2013 3950 3956
62. B.H. Cho, C. Stoecker, R. Link-Gelles, and M.R. Moore Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions Vaccine 31 2013 6011 6021
63. M. Lujan, J. Burgos, and M. Gallego Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies Clin Infect Dis 57 2013 1722 1730
64. L.G. Rubin, M.J. Levin, and P. Ljungman 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host Clin Infect Dis 58 2014 e44 100
65. A.M. Ellison, K.V. Ota, K.L. McGowan, and K. Smith-Whitley Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population Pediatr Infect Dis J 31 2012 534 536
66. A. Patel, A. Zuzo, H. Imran, and A.H. Siddiqui Prevalence of pneumococcal bacteremia in children with sickle cell disease Pediatr Hematol Oncol 30 2013 432 436
67. R. Vij, and R.F. Machado Pulmonary complications of hemoglobinopathies Chest 138 2010 973 983
68. R.S. Geha, L.D. Notarangelo, and J.L. Casanova Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee J Allergy Clin Immunol 120 2007 776 794
69. R.H. Buckley Pulmonary complications of primary immunodeficiencies Paediatr Respir Rev 5 Suppl A 2004 S225 S233
70. P.J. Turner, S. Mehr, and A.S. Kemp Detection of pulmonary complications in common variable immunodeficiency Pediatr Allergy Immunol 22 2011 449 450 author reply 51-52
71. C.M. Touw, A.A. van de Ven, and P.A. de Jong Detection of pulmonary complications in common variable immunodeficiency Pediatr Allergy Immunol 21 2010 793 805
72. C. Picard, A. Puel, and J. Bustamante Primary immunodeficiencies associated with pneumococcal disease Curr Opin Allergy Clin Immunol 3 2003 451 459
73. J. Bustamante, S.Y. Zhang, and H. von Bernuth From infectious diseases to primary immunodeficiencies Immunol Allergy Clin North Am 28 2008 235 258 vii
74. J.A. Winkelstein, M.C. Marino, and R.B. Johnston Jr. Chronic granulomatous disease. Report on a national registry of 368 patients Medicine 79 2000 155 169
75. C.F. Barnett, and P.Y. Hsue Human immunodeficiency virus-associated pulmonary arterial hypertension Clin Chest Med 34 2013 283 292
76. O. Sitbon, V. Gressin, and R. Speich Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension Am J Respir Crit Care Med 170 2004 1212 1217
77. A.A. Lambert, C.A. Merlo, and G.D. Kirk Human immunodeficiency virus-associated lung malignancies Clin Chest Med 34 2013 255 272
78. S.M. Graham HIV-related pulmonary disorders: practice issues Ann Trop Paediatr 27 2007 243 252
79. M.R. Gingo, A. Morris, and K. Crothers Human immunodeficiency virus-associated obstructive lung diseases Clin Chest Med 34 2013 273 282
80. R. Masekela, R. Anderson, and T. Moodley HIV-related bronchiectasis in children: an emerging spectre in high tuberculosis burden areas Int J Tuberc Lung Dis 16 2012 114 119
81. Y.L. Ho, A.P. Brandao, M.C. de Cunto Brandileone, and M.H. Lopes Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil Vaccine 31 2013 4047 4053
82. A. Wong, T.J. Marrie, and S. Garg Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies Epidemiol Infect 138 2010 1804 1810
83. R. Meisel, A.M. Toschke, and C. Heiligensetzer Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia Br J Haematol 137 2007 457 460
84. K. Debbache, E. Varon, and Y. Hicheri The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect 15 2009 865 868
85. M.C. Kapetanovic, C. Roseman, G. Jonsson, and L. Truedsson Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs Clin Rheumatol 30 2011 1555 1561
86. L.G. Visser TNF-alpha antagonists and immunization Curr Infect Dis Rep 13 2011 243 247
87. P. Korsten, M. Mirsaeidi, and N.J. Sweiss Nonsteroidal therapy of sarcoidosis Curr Opin Pulm Med 19 2013 516 523
88. R.W. Frenck Jr., A. Gurtman, and J. Rubino Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults Clin Vaccine Immunol 19 2012 1296 1303